Indaptus Shareholders Approve Major Charter and Capital Changes

Indaptus Therapeutics ( (INDP) ) has issued an update.

On February 26, 2026, Indaptus Therapeutics held a special shareholders’ meeting at which investors elected Jerome Jabbour as a Class I director through the 2028 annual meeting and Matthew McMurdo as a Class III director through the 2027 meeting, with approximately 34.7% of outstanding common shares represented. Stockholders also approved multiple Nasdaq-related share issuance proposals, authorizing the issuance of common stock upon conversion of Series AA and Series AAA preferred shares, including shares issuable to the company’s co-chief executive officer and chairman.

Investors further backed amendments to the charter to permit two reverse stock splits at ratios between 1-for-2 and 1-for-199, to be implemented at the board’s discretion, as well as an expansion of authorized common shares from 200 million to up to 1 billion. A charter amendment to allow shareholder action by written consent in lieu of a meeting was approved and became effective via a Certificate of Amendment filed in Delaware on February 27, 2026, giving the company greater flexibility in capital raising and corporate actions while potentially increasing future dilution risk for existing shareholders.

The most recent analyst rating on (INDP) stock is a Sell with a $1.50 price target. To see the full list of analyst forecasts on Indaptus Therapeutics stock, see the INDP Stock Forecast page.

Spark’s Take on INDP Stock

According to Spark, TipRanks’ AI Analyst, INDP is a Neutral.

The score is held down primarily by weak financial performance (no revenue, sizable ongoing losses, and continued cash burn alongside a diminished equity/asset base). Technicals also remain bearish with the stock trading below all major moving averages and a negative MACD, despite oversold readings. Valuation provides limited support due to negative earnings and no dividend, while recent corporate events are mixed but secondary to the financial and trend risks.

To see Spark’s full report on INDP stock, click here.

More about Indaptus Therapeutics

Indaptus Therapeutics operates in the biopharmaceutical sector and is listed on Nasdaq, issuing common stock and multiple series of convertible preferred stock. The company’s governance structure includes a classified board, and its capital strategy relies on the flexibility to issue large volumes of equity and to adjust its share structure through mechanisms such as reverse stock splits.

Average Trading Volume: 715,452

Technical Sentiment Signal: Strong Sell

Current Market Cap: $4.51M

See more data about INDP stock on TipRanks’ Stock Analysis page.